Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease Type (Schizophrenia, Bipolar Disorder, Dementia, Unipolar Depression, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By End-Users (Veterinary Hospitals, Hog Production Farm) Based On Region, And Segment Forecasts, 2022 - 2028

  • Report ID: BMRC 1960 | Number of pages: 199 | Published Date: Jun 2022

    Published | Category: Healthcare | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease Type (Schizophrenia, Bipolar Disorder, Dementia, Unipolar Depression, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By End-Users (Veterinary Hospitals, Hog Production Farm) Based On Region, And Segment Forecasts, 2022 - 2028 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

Global Antipsychotic Drugs Market is valued at USD 14.37 Billion in 2021 and expected to reach USD 22.89 Billion by 2028 with a CAGR of 6.87% over the forecast period

Global Antipsychotic Drugs Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2028- Increasing incidences of mental disorders, rising number of product launches of antipsychotic drugs, and growing geriatric populations are major factors anticipated to drive the growth of Global Antipsychotic Drugs Market.

Scope of Global Antipsychotic Drugs Market Report:-

Antipsychotics drugs are drugs that are used to treat symptoms of psychosis-like delusions, confused thoughts, hallucinations, paranoia. Severe anxiety, schizophrenia, and severe anxiety can be treated with antipsychotic drugs. Antipsychotics also are useful at stabilizing episodes of mania in people with manic depression. Disorganized thinking, trouble in concentrating and memory problems can be controlled by antipsychotics. Antipsychotic medications are generally divided into two types atypical (second generation) antipsychotics and typical (first generation) antipsychotics. Antipsychotic drugs are used to treat people with psychosis that occurs in bipolar disorder, depression and Alzheimer’s disease. Bipolar disorders, anxiety, reducing anxiety in anxiety disorders and reducing tics in Tourette syndrome also some of the uses of antipsychotic drugs.

The Covid-19 pandemic has shown a positive effect on the global antipsychotic drugs market. The Covid-19 pandemic affected physical health as well as mental health of people due to lockdown. The financial burden caused anxiety and depression. The restrictions affected the mental well-being across globe. The people working from home were more stressed managing work and children’s online school. The anxiety and fear of catching or dying from the virus and overall situation led to increase the consumption for antipsychotic drugs and positively impacted the market.

Report Analysis Details
Historical data 2018 - 2021
Forecast Period 2021 - 2028
Market Size in 2021: USD 14.37 Billion 
Base year considered 2020
Forecast Period CAGR %:

6.87% 

Market Size Expected in 2028: USD 22.89 Billion 
Tables, Charts & Figures: 175
Pages 200
Antipsychotic Drugs Companies Dr. Reddy's Laboratories, GlaxoSmithKline plc, Eli Lily Company, Johnson & Johnson, AstraZeneca plc, Teva Pharmaceuticals, Otsuka Pharmaceutical Co, Ltd., Bristol-Myers Squibb, Pfizer Inc., AbbVie Inc., others.
Segments Covered By Disease Type, By Distribution Channel, By End-Users
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Global Antipsychotic Drugs Market Segmentation:-

The global antipsychotic drugs market is segmented on the basis of disease type, drug class, distribution channel, end-user and region & country level. On the basis of disease type, the global antipsychotic drugs market has been segmented into schizophrenia, bipolar disorder, dementia, and unipolar depression. On the basis of distribution channels, the market is segmented into hospital pharmacy, online pharmacy and retail pharmacy. On the basis of end-users, the global antipsychotic drug market is segmented into hospitals, home care, specialty clinics and others.

By Disease Type:

  • Schizophrenia
  • Bipolar Disorder
  • Dementia
  • Unipolar Depression
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By End-Users:

  • Veterinary Hospitals
  • Hog Production Farm

Key Players for Global Antipsychotic Drugs Market Report:-

Some of the key players for global antipsychotic drugs market are

  • Dr. Reddy's Laboratories
  • GlaxoSmithKline plc
  • Eli Lily Company
  • Johnson & Johnson
  • AstraZeneca plc
  • Teva Pharmaceuticals
  • Otsuka Pharmaceutical Co, Ltd.
  • Bristol-Myers Squibb
  • Pfizer Inc.
  • AbbVie Inc.
  • others.

Antipsychotic Drugs Market

Recent Developments

News- Intra-Cellular Therapies Announced U.S. FDA Approval of CAPLYTA (lumateperone) for the Treatment of Bipolar Depression in Adults

On December 20th, 2021; U.S Food and Drug Administration approved Intra-Cellular Therapies, Inc. a biopharmaceutical company focusing on the development and commercialization of therapeutics for central nervous system (CNS) disorders, approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate. CAPLYTA is that the only medication approved by the FDA to treat depressive disorders related to bipolar I or bipolar II as both monotherapy and adjunctive therapy with lithium or valproate. CAPLYTA has shown a uniform favorable profile on weight, cardiometabolic parameters and extrapyramidal symptoms.

Alkermes Announced FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder

On June 1st, 2021; U.S Food and Drug Administration announced approval of Alkermes plc. LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. LYBALVI is composed of olanzapine prescribed as once-daily. LYBALVI proved antipsychotic efficacy, safety and tolerability, including statistically significantly less weight gain than olanzapine in patients with schizophrenia in the ENLIGHTEN-2 study. LYBALVI is co-formulated with samidorphan, in a single bilayer tablet. 10 mg of samidorphan and 5mg, 10mg, 15mg or 20mg of olanzapine doses are available for the LYBALVI tablet.

Increasing Incidences of Mental Disorders, Rising Number of Product Launches and Growing Geriatric Population are Major Factors Anticipated to Drive the Market Growth

One of the major factors driving the market growth is the increasing prevalence of mental disorders. Competition in education, financial burden, as well as poverty, unemployment, life events such as the death of a loved one, physical illness, sedentary lifestyle, work stress, family problems and addictions of alcohol and drug use all these situations caused increase in mental disorders and mental health of people is got disturbed. Thus, these consequences led to increase in mental disorders which will increase demand for antipsychotic drug. For instance; depression is most common disorder and it is global burden, each year 5% adults suffer from depression in their life as per World Health Organization worldwide. Depression is serious concern as it led to suicidal thoughts.

In addition, rising number of product launches are also supplementing the growth of the market. The use of antipsychotic drugs lessening psychotic symptoms and the risk of a numerous adverse effects. Antipsychotic drugs frequently decline the power of hallucinations. Thus, key players are focused on the development of novel antipsychotic drugs and this factor is expected to boost the growth of the global antipsychotic drugs market in the forecast period. For instance; on June 1st, 2020; Alkermes announced FDA approval of LYBALVI for the treatment of schizophrenia and bipolar I disorder.

Moreover, rising geriatric population is also supplementing the market growth. Psychological conditions are common in old age people due to weakness, financial stress, age gap in communication which led to endure the psychological effects. Mental disorders are common among elderly people such as anxiety disorders include GAD, agoraphobia, panic anxiety disorder, OCD, social phobia, and specific phobias. For instance, as per World Health Organization about 15% of adults aged 60 and over suffer from a mental disorder. Furthermore, advances in medical treatments and rising awareness programmes about metal health are also anticipated to drive the growth of the market. However, high cost of antipsychotic drugs and side effects associated with antipsychotic drugs may limit the growth of the market. In spite of that, rising awareness regarding mental health may offer more opportunities for the further growth of the market.

North America Expected to Dominate the Global Antipsychotic Drugs Market

North America is expected to dominate the global antipsychotic drugs market due to rising prevalence of schizophrenia, high awareness regarding mental health and growing adoption of antipsychotic drugs. For instance; according to the Schizophrenia and Related Disorders Alliance of America; 3.5 million Americans have been diagnosed with schizophrenia in 2020. Thus, the rising prevalence and increasing incidence of schizophrenia is boosting the growth of the anti-psychotic drugs market. In addition to that, high awareness about the mental health in North America is augmenting the growth of the market as the different strategies and prevention techniques were carried for promoting mental health awareness. Moreover, growing adoption of psychotic drugs is also boosting the market growth. For instance; on December 20th, 2021, Food and Drug Administration (FDA) approved Intra-Cellular Therapies CAPLYTA (lumateperone) for the treatment of bipolar depression in adults.

The Asia Pacific is expected to capture a significant share in the global antipsychotic drugs market due to the growing prevalence of mental disorders, rising awareness about mental health and launching of new antipsychotic drugs. For example; 38 million people had depression in 2020 according to World Health Organization. These increasing number of mental disorders will increase the growth of the antipsychotic drugs for the need of treatment. In addition, rising awareness about psychotic disorders by government and social media influencers are also adding the growth to the market. For instance, on September 5th, 2019; an awareness programme conducted by Cadila Pharmaceuticals with Compassion program for Depression. Furthermore, new product launches are also providing growth to the market as product launch by key players in this region. For instance; on February 18th, 2021 the launch of Fluphenazine Hydrochloride Tablets as announced by Dr. Reddy's Laboratories which is a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg and 10mg for the treatment of mental or mood problems.

On Special Requirement Antipsychotic Drugs Market Report is also available for below Regions and Country:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA

Key Benefits in Global Antipsychotic Drugs Market Report-

  • Global Antipsychotic Drugs Market report covers in-depth historical and forecast analysis.
  • Global Antipsychotic Drugs Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country levels.
  • Global Antipsychotic Drugs Market report helps to identify opportunities in the marketplace.
  • Global Antipsychotic Drugs Market report covers extensive analysis of emerging trends and the competitive landscape.


Frequently Asked Questions (FAQ) :
The Antipsychotic Drugs Market revenue is expected to expand at a CAGR of 6.87% during the forecast period.
Global Antipsychotic Drugs Market Size is Projected to Garner USD 22.89 Billion by 2028 with a CAGR of 6.87% over the forecast period.
Dr. Reddy's Laboratories, GlaxoSmithKline plc, Eli Lily Company, Johnson & Johnson, AstraZeneca plc, Teva Pharmaceuticals, Otsuka Pharmaceutical Co, Ltd., Bristol-Myers Squibb, Pfizer Inc., AbbVie Inc., others.
Increasing incidences of mental disorders, rising number of product launches of antipsychotic drugs, and growing geriatric populations are major factors anticipated to drive the growth of Global Antipsychotic Drugs Market.
North America Expected to Dominate the Global Antipsychotic Drugs Market.



Interested in this report?

Antipsychotic Drugs Market Share, Size, Industry Trends Analysis, And Growth By 2028

report cover

Request for Table of Content

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease Type (Schizophrenia, Bipolar Disorder, Dementia, Unipolar Depression, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By End-Users (Veterinary Hospitals, Hog Production Farm) Based On Region, And Segment Forecasts, 2022 - 2028

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.
Brandessence market research actively tracks, monitors, and analyses key industry trends in real-time via B2B surveys in 60 + countries and territories.

    Pricing


Looking for Regional Reports?